## September 30, 2017

## **Neuroendocrine Cancer Regional Conference**

Buffalo Marriott Niagara 1340 Millersport Highway Amherst, New York 14221

R MILE

Registration Fees: \$60 for physicians \$30 for other medical professionals FREE for residents, fellows & students *RPCI use special code* 

HAN

J HANK



Roswell Park Cancer Institute designates this live activity for a maximum of 5.50 AMA PRA Category 1 Credit(s)<sup>™</sup>

N ZNL

## **AGENDA**

## Saturday – September 30, 2017

8:15 am – 8:45 am	Registration & Breakfast
8:45 am – 8:50 am	Welcome & Opening Remarks – Kari Brendtro & Srinevas Reddy
8:50 am - 10:00 am	SESSION 1 : Diagnostic Approaches & Surveillance
	General Overview – Sunyoung Lee, MD
	Principals of Pathology for Diagnosis of Pancreatic & Intestinal NETs – Jon Strosberg, MD
	Imaging Modalities and Applications
	<ul> <li>Optimizing Anatomical/Cross-sectional Imaging – Charles Roche, MD         <ul> <li>Choosing the Right Modality &amp; Sequence</li> <li>Staging &amp; Treatment Selection</li> </ul> </li> </ul>
	<ul> <li>Molecular Imaging - Daniel Pryma, MD         <ul> <li>Functional Imaging: Role &amp; Limitations</li> <li>Diagnosis &amp; Staging</li> <li>Imaging Algorithm, Appropriate Use Criteria &amp; NCCN Guidelines</li> <li>Evolving Role of Nuclear Medicine Imaging &amp; Current Clinical Trials</li> </ul> </li> <li>Q &amp; A (15 min)</li> </ul>
10:00 am - 11:10 am	SESSION 2 : Surgical Challenges & Controversial Issues for Management of NETs
	Surgical Assessment – Moshim Kukar, MD         O Goal of Surgery         O Patient Selection (Age, Performance Status, Co-morbidities)         O Preoperative Evaluation

	<ul> <li>Preoperative Evaluation</li> <li>Do Symptoms Influence Surgical Decisions?</li> <li>Should Liver Lesions be Resected at Time of Primary Surgery?</li> </ul>
	<ul> <li>Open vs Laparoscopic Resections – Which is the Optimal Strategy?         <ul> <li>Small Bowel NET- Moshim Kukar, MD</li> <li>Use of Octreotide – Is it Necessary?</li> <li>Surgical Approach</li> <li>Prophylactic Cholecystectomy</li> </ul> </li> <li>Pancreatic NET – Steven Hochwald, MD</li> <li>Functional vs Nonfunctional</li> <li>Segmental Resections - What is the Criterion?</li> <li>Distal Pancreatectomy (w/wo splenectomy)</li> <li>Panreaticoduodenectomy</li> </ul> <li>Surgical Exploration – Lindy Davis, MD         <ul> <li>High Grade – Should Surgery Be Considered?</li> <li>Unknown Primary – Is it Important to Find It?</li> </ul> </li>
	<ul> <li>Onknown Primary – Is it Important to Find It?</li> <li>Contraindications</li> <li>Hepatic Surgery for Metastatic NETs – Srinevas Reddy, MD         <ul> <li>Survival Advantages &amp; Other Benefits of R0, R1 &amp; R2 Resections</li> <li>Hepatic Resections &amp; Liver Directed Therapy</li> </ul> </li> <li>Evolving Role of the NET Surgeon – Srinevas Reddy, MD         <ul> <li>Recurrence of Metastases</li> <li>Peritoneal and Diaphragmatic Metastases</li> <li>Nodal Management</li> </ul> </li> </ul>
11:10 am – 11:25 am	BREAK
11:25 am – 12:20 pm	SESSION 3: Therapies for Symptom & Tumor Control
	<ul> <li>Carcinoid Syndrome Symptom Control - Hassan Hatoum, MD</li> <li>Somatostatin Analogs (SSA's - octreotide, lanreotide)         <ul> <li>Mechanisms of Action</li> <li>Long Term Use</li> <li>Refractory Diarrhea</li> <li>SSA's Role in Disease Stabilization</li> </ul> </li> </ul>
	<ul> <li>Other Symptom Control – Hassan Hatoum, MD</li> <li>Managing Persistent/Recurrent Diarrhea Not Associated with Carcinoid Syndrome         <ul> <li>Pancreatic Insufficiency from SSA Use (Pancreatic &amp; Digestive Enzymes)</li> <li>Biliary Salt Malabsorption, Short Gut Syndrome, Bacterial Overgrowth</li> <li>Nutritional Support</li> </ul> </li> </ul>

	Medical Management for Progressive Disease- Thorvadur Halfdanarson, MD
	GI NETS
	<ul> <li>mTOR Inhibition         <ul> <li>Mechanisms of Action</li> <li>RADIANT 4 – (Everolimus)</li> </ul> </li> </ul>
	Anti-angiogenic Therapy     O Bevacizumab
	Other Combination Therapies     O Use with SSA's
	Pancreatic NETs
	<ul> <li>Targeted Therapies         <ul> <li>Tyrosine Kinase Inhibitors (Sunitinib)</li> <li>mTOR Inhibition – (Everolimus)</li> </ul> </li> </ul>
	<ul> <li>Chemotherapy         <ul> <li>Temozolamide</li> <li>Streptozosin</li> <li>Combination Therapies</li> </ul> </li> </ul>
	Poorly Differentiated NETs
	<ul> <li>Heterogeneity         <ul> <li>Differences in Clinical Behavior</li> <li>Nordic Study</li> <li>New WHO Classification?</li> </ul> </li> <li>Platinum Based Therapies</li> </ul>
	<ul> <li>Capecitabine/Temozolomide Combination</li> </ul>
	Current Clinical Trials Q & A (10 min)
12:20 pm – 12:30 pm	SESSION 4: Roswell Park NET Registry – Renuka Iyer, MD
· · ·	
12:30 pm – 1:00 pm	SESSION 5: Case Presentations – Small Bowel & Pancreatic NET (Moshim Kukar/Thorvadur Halfdanarson)
1:00 pm – 1:30 pm	LUNCH
1:30 pm – 2:30 pm	SESSION 6: Pulmonary NETs: Challenges in Diagnosis and Management
	<ul> <li>Overview &amp; Diagnosis -Renuka Iyer,MD         <ul> <li>Epidemiology</li> <li>Pathology</li> <li>Differential Diagnosis</li> </ul> </li> </ul>
	Surgical Resection – Sai Yendamuri, MD         O Localized Disease in Peripheral         O Localized Disease in Central Airway

	<ul> <li>Localized Disease in Central Airway</li> <li>Systemic Nodal Dissection</li> <li>Local Resection - When should Endobronchial or Peripheral Ablation be Considered?</li> <li>Metastatic Disease</li> <li>Recurrent Disease</li> </ul>
	<ul> <li>Medical Therapy – Thorvadur Halfdanarson, MD         <ul> <li>Control of Hormonal Symptoms &amp; Tumor Control</li> <li>Adjuvant Therapies</li> <li>Targeted Therapies</li> <li>Chemotherapy</li> </ul> </li> </ul>
	• Follow-up
	Future Considerations & Current Clinical Trials
	<b>Q &amp; A</b> (10 min)
2:30 pm – 3:00 pm	SESSION 7: Radiolabeled Peptides - A New Era in Treatment of NETs – Jonathan Strosberg, MD
	<ul> <li>Background &amp; European Clinical Experience</li> <li>Selection Criteria         <ul> <li>Risk Factors</li> <li>Krenning Score &gt;2</li> <li>Type of Previous Treatments</li> </ul> </li> <li>NETTER 1 Trial – Study Objectives &amp; Design</li> <li>Preventing Toxicities &amp; Nausea         <ul> <li>Kidney Protection (Amino Acid Infusion)</li> <li>Radiation or MDS</li> </ul> </li> <li>Where Should PRRT Be in the Treatment Paradigm?</li> <li>Get Prepared</li> <li>Future Directions &amp; Current Clinical Trials         <ul> <li>Q &amp; A (10 min)</li> </ul> </li> </ul>
3:00 pm	Closing Remarks & Adjourn – <i>Renuka Iyer, MD</i>